Epidemiology & Risk Factors

  • Demographics: F > M (approx. 3:1), peak incidence in young adults (ages 20–40).
  • Hypercoagulable States:
    • Pregnancy & Postpartum (highest risk in peripartum/puerperium).
    • Estrogen-containing OCPs / HRT.
    • Inherited thrombophilias (Factor V Leiden, Prothrombin G20210A mutation, Protein C/S deficiency, Antithrombin III deficiency).
    • Acquired thrombophilias: Antiphospholipid syndrome (APS), malignancy, nephrotic syndrome.
  • Local / Systemic Infections:
    • Sinusitis, mastoiditis, otitis media, “danger triangle” facial skin infections (leads to septic cavernous sinus thrombosis).
  • Systemic Inflammatory Diseases:
    • Behçet disease, SLE, IBD, systemic vasculitis.
  • Mechanical / Others:
    • Head trauma, neurosurgical procedures, severe dehydration (especially in neonates/pediatrics).

Clinical Features

  • History:
    • Headache (>90%): Most common initial symptom; gradual, progressive, worsens with recumbency, coughing, or Valsalva (signs of ↑ ICP). Rarely presents as a “thunderclap” headache. c
    • Seizures (~40%): Focal or generalized (significantly higher frequency than in arterial ischemic stroke).
    • Altered Mental Status (AMS): Lethargy, confusion, encephalopathy, or coma in severe cases.
  • Physical Examination:
    • Papilledema and visual obscurations secondary to elevated ICP.
    • Focal Neurologic Deficits (FND): Hemiparesis, aphasia, or bilateral/alternating motor deficits (due to parasagittal cortex involvement from superior sagittal sinus occlusion).
    • Cranial Nerve Palsies:
      • CN VI palsy (false localizing sign of ↑ ICP).
      • Cavernous Sinus Thrombosis: Chemosis, proptosis, ptosis, painful ophthalmoplegia involving CN III, IV, V1, V2, and VI.

Diagnosis

  • Initial Imaging:
    • Non-contrast CT Head: Often normal (~30%); may show hyperdense cord sign, non-arterial territory edema, or hemorrhagic infarction.
  • Confirmatory / Gold Standard Imaging:
    • MR Venography (MRV) or CT Venography (CTV): MRV is the preferred test; demonstrates lack of flow void and intraluminal filling defect.
    • Contrast-enhanced CT/MRI: “Empty delta sign” (contrast enhancement of collateral dural vessels outlining a non-enhancing clot in the superior sagittal sinus).
  • Key Labs:
    • D-dimer: Elevated in acute phase (normal D-dimer does not completely exclude CVST if suspicion is high).
    • Baseline CBC, PT/INR, PTT, renal/hepatic panels.
    • Hypercoagulability workup (best drawn after acute phase and anticoagulation completion).
    • Blood cultures (if septic cavernous sinus thrombosis or infectious etiology is suspected).
  • Lumbar Puncture (LP):
    • Indicated if meningitis/idiopathic intracranial hypertension suspected (perform only after imaging rules out mass effect/herniation risk). Shows elevated opening pressure (>20–25 cm H2O).

Differential Diagnostics

  • Idiopathic Intracranial Hypertension (IIH / Pseudotumor Cerebri):
    • Diff by normal MRV/CTV without venous sinus thrombosis or parenchymal infarction; typically seen in obese females of reproductive age.
  • Arterial Ischemic Stroke:
    • Diff by sudden maximal deficit restricted to a specific single arterial vascular territory (e.g., MCA), absence of severe early headache, and lower incidence of early seizures.
  • Subarachnoid Hemorrhage (SAH):
    • Diff by hyperacute “worst headache of life”, blood localized to subarachnoid cisterns/sulci on non-contrast CT, and xanthochromia on LP.
  • Bacterial / Viral Meningitis:
    • Diff by prominent fever, marked nuchal rigidity (Kernig/Brudzinski signs), and CSF pleocytosis with positive Gram stain/microbiology.
  • Brain Abscess / Neoplasm:
    • Diff by ring-enhancing lesion or discrete intraparenchymal mass on contrast imaging with surrounding vasogenic edema.

Management

  • First-line / Acute Phase:
    • Therapeutic Anticoagulation: Immediate initiation of LMWH (subcutaneous) or UFH (IV).
      • High-Yield Step 2 Rule: Anticoagulation is indicated even in the presence of hemorrhagic venous infarction.
    • Transition to oral anticoagulation (DOACs or Warfarin target INR 2.0–3.0) once clinically stabilized.
    • Duration:
      • 3–6 months for provoked/transient risk factors (e.g., infection, OCPs).
      • 6–12 months or lifelong for unprovoked CVST, recurrent thrombosis, or severe thrombophilia (e.g., APS, homozygous Factor V Leiden).
  • Supportive & Symptom Management:
    • Seizure Management: Antiseizure medications (e.g., Levetiracetam) if seizures occur. Routine primary prophylaxis without seizures is not recommended unless focal supratentorial cortical lesions are present.
    • Elevated ICP Management: Head-of-bed elevation (30°), hypertonic saline or IV Mannitol for impending herniation. Acetazolamide or therapeutic LP if persistent elevated ICP without herniation risk.
    • Infectious CVST (Septic Cavernous Sinus Thrombosis):
      • Empiric broad-spectrum IV antibiotics: Vancomycin + Ceftriaxone/Cefepime + Metronidazole.
      • Urgent ENT/Surgical drainage of primary source (sinus, mastoid, dental abscess).
  • Refractory / Second-line:
    • Endovascular Mechanical Thrombectomy / Local Thrombolysis: Reserved for clinical deterioration despite therapeutic anticoagulation.
    • Decompressive Hemicraniectomy: For severe mass effect, large hemorrhagic infarct, or impending transtentorial herniation.

Complications

  • Hemorrhagic venous infarction with secondary mass effect.
  • Transtentorial / Uncal herniation and death.
  • Status epilepticus.
  • Permanent visual loss secondary to severe, sustained papilledema and optic atrophy.
  • Dural arteriovenous fistula (dAVF) (delayed vascular complication).